U.S. patent application number 12/009431 was filed with the patent office on 2009-01-29 for methods for detecting parenchymal plaques in vivo.
Invention is credited to Geoffry L. Curran, Joseph F. Poduslo, Thomas M. Wengenack.
Application Number | 20090028789 12/009431 |
Document ID | / |
Family ID | 46298944 |
Filed Date | 2009-01-29 |
United States Patent
Application |
20090028789 |
Kind Code |
A1 |
Poduslo; Joseph F. ; et
al. |
January 29, 2009 |
Methods for detecting parenchymal plaques in vivo
Abstract
Methods for detecting parenchymal plaque deposits in the brain
of a living mammal are described that include administering a
polyamine modified, labeled polypeptide having specific binding
affinity for the extracellular deposit, to the living mammal.
Isolated .beta.-amyloid peptides that are polyamine modified and
labeled with a radioisotope or contrast agent also are
described.
Inventors: |
Poduslo; Joseph F.;
(Rochester, MN) ; Curran; Geoffry L.; (Rochester,
MN) ; Wengenack; Thomas M.; (Rochester, MN) |
Correspondence
Address: |
QUARLES & BRADY LLP
411 E. WISCONSIN AVENUE, SUITE 2040
MILWAUKEE
WI
53202-4497
US
|
Family ID: |
46298944 |
Appl. No.: |
12/009431 |
Filed: |
January 18, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10351777 |
Jan 27, 2003 |
7371365 |
|
|
12009431 |
|
|
|
|
09542537 |
Apr 4, 2000 |
|
|
|
10351777 |
|
|
|
|
60427821 |
Nov 20, 2002 |
|
|
|
Current U.S.
Class: |
424/1.69 ;
424/9.34; 530/391.3 |
Current CPC
Class: |
A61K 49/0002
20130101 |
Class at
Publication: |
424/1.69 ;
424/9.34; 530/391.3 |
International
Class: |
A61K 51/00 20060101
A61K051/00; A61K 49/00 20060101 A61K049/00; C07K 16/18 20060101
C07K016/18 |
Claims
1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. An isolated antibody having specific binding affinity for a
.beta.-amyloid peptide wherein said antibody is polyamine modified
and labeled with a radioisotope or contrast agent suitable for
diagnostic imaging.
21. The antibody of claim 20, wherein said .beta.-amyloid peptide
is .beta.-amyloid peptide.sub.1-40.
22. The antibody of claim 20, wherein said antibody is labeled with
a contrast agent.
23. The antibody of claim 22, wherein said contrast agent is
selected from the group consisting of Gd, dysprosium, and iron.
24. The antibody of claim 22, wherein said contrast agent is
Gd.
25. The antibody of claim 20 wherein said antibody is labeled with
a radioisotope.
26. The antibody of claim 25 wherein said radioisotope is selected
from the group consisting of .sup.123I, .sup.18F, .sup.111In,
.sup.67Ga, and .sup.99mTc.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/351,777 filed Jan. 27, 2003, which claims benefit to
U.S. Provisional Application 60/427,821 filed Nov. 20, 2002 and is
a continuation-in-part of U.S. patent application Ser. No.
09/542,537, filed Apr. 4, 2000. These applications are incorporated
by reference herein.
TECHNICAL FIELD
[0002] This invention relates to detecting extracellular deposits
such as plaques in the brain of a living mammal, and more
particularly to using a polyamine-modified, labeled polypeptide as
a contrast agent which enables the plaques to imaged.
BACKGROUND
[0003] Alzheimer's disease is a devastating disease of the brain
which results in progressive dementia, physical disability and
death over a relatively long period of time. With the aging
population in the United States and other countries, the number of
Alzheimer's patients is rapidly rising and can accurately be
characterized as a silent epidemic. Much research is being
conducted to develop drugs that will slow or halt the progression
of the disease, and there is hope that a vaccine or inhibitors of
secretase may ultimately be developed.
[0004] One of the difficulties in managing this disease is the lack
of means for its early detection and means for measuring its
progression. Such means are needed to identify persons who should
receive treatment and to measure the effectiveness of the
treatment. An immediate problem is the need for a method which
measures the progression of the disease in order to evaluate the
effectiveness of the many drugs being developed.
[0005] Many techniques have been proposed for detecting and
measuring the progress of Alzheimer's disease. These include
cognitive tests which attempt to measure brain functions by having
the patient perform different tasks. The problem with this approach
is that it does not distinguish between dementia caused by
Alzheimer's disease and dementia caused by other factors. In
addition, the ability to measure the progression of the disease
using cognitive tests is very limited.
[0006] Neurofibrillary tangles (NFTs) and neuritic plaques (NPs)
are the classical neuropathological hallmarks of Alzheimer's
disease. Numerous neuropathological studies indicate that the first
appearance of NFTs and NPs in the hippocampal region of the brain
marks the beginning of the degenerative process. Many studies have
been done in which the structure of the brain has been imaged to
determine structural changes that are linked to the presence and
the progression of Alzheimer's disease. These include: 2-D
estimates of size; measures of medical temporal lobe gray matter
volume; the qualitative rating of the amount of CSF accumulating in
the hippocampal fissures, the size of the suprasellar cistern; and
the increased distance between the right and left uncus. None of
have been particularly successful, and in fact, it has been found
that profound structural changes can occur in the brain of some
individuals with no cognitive impairment or other symptoms of the
disease being evident.
[0007] Alzheimer's Disease (AD) is characterized
neuropathologically by neuritic plaques and neurofibrillary
tangles. Neuritic or senile plaques contain a dense core consisting
largely of several species of amyloid-.beta. (A.beta.) peptide.
A.beta. is a 39-43 amino acid peptide derived from amyloid
precursor protein. AP is highly hydrophobic and spontaneously
aggregates in vitro to form D pleated sheets. Maggio, J. E. and
Mantyh, P. W., Brain Pathol., 6:147-162 (1996). A.beta. also has
been reported to be neurotoxic in vitro and in vivo. The main link
between AD and A.beta. is based on genetic mutations that have been
discovered in familial forms of AD and Down's syndrome that result
in aberrant processing or increased levels and deposition of
A.beta.. Selkoe, D. J., Science, 275:630-631 (1997). Furthermore,
transgenic mice overexpressing the same mutations have been shown
to develop amyloid deposits like those in AD as well as significant
behavioral deficits. Hsiao, K., et al., Science 274:99-102 (1996);
and Holcomb, L., et al., Nature Med., 4:97-100 (1998). There also
appears to be a significant correlation between amyloid burden and
dementia in AD patients.
[0008] Currently, there is no definitive diagnosis for AD except by
post-mortem observation of these deposits and a process of
elimination of other neurodegenerative disorders.
SUMMARY
[0009] In one embodiment, the present invention is a method for
detecting parenchymal plaque deposits in the brain of a living
mammal. The method comprises: a) administering an amount of a
polypeptide to a mammal effective to detectably bind to parenchymal
plaque deposits, wherein the polypeptide is labeled with a contrast
agent and is polyamine modified, and wherein the polypeptide has
specific binding affinity for said deposits; and b) detecting the
polypeptide bound to the deposits. The detecting step comprises
acquiring nuclear magnetic resonance image data and reconstructing
an image therefrom.
[0010] In a preferred embodiment, the deposits are .beta.-amyloid
plaques and the polypeptide is a .beta.-amyloid peptide, such as
.beta.-amyloid peptide.sub.1-40 or derivatives thereof.
[0011] In another preferred embodiment, the polyamine is
putrescine.
[0012] In another embodiment, the present invention is a method for
producing an image with a magnetic resonance imaging (MRI) system
which indicates parenchymal plaques in the brain of a subject.
Preferably, the steps comprise: a) acquiring a reference image data
set of the brain with the MRI system; b) injecting into the
subject's vascular system a contrast agent comprised of a labeled
polypeptide having a specific binding affinity for said plaques and
being polyamine modified to enhance transit through and exit from
capillary endothelial cells to the brain parenchyma; c) waiting for
a time period sufficient for the contrast agent to bind to said
parenchymal plaques and for unbound contrast agent to diffuse in
the subject; d) acquiring a contrast enhanced image data set of the
brain with the MRI system; and e) reconstructing an image of the
brain which indicates at each of its image pixels the difference in
NMR signal magnitude between the contrast enhanced image data set
and the reference image data set.
[0013] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used to practice the invention, suitable methods and
materials are described below. All publications, patent
applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including definitions, will control. In
addition, the materials, methods, and examples are illustrative
only and not intended to be limiting.
[0014] Other features and advantages of the invention will be
apparent from the following detailed description and from the
claims.
DESCRIPTION OF DRAWINGS
[0015] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0016] FIGS. 1A and 1B are RP-HPLC chromatograms of unlabeled
A.beta..sub.1-40 (A) and PUT-A.beta..sub.1-40 (B). The abscissa
plots the retention time in minutes. The left ordinate plots the
absorbance at 214 nm. The right ordinate plots the gradient as
percent of Buffer B (80% ACN/0.05% TFA/19.95% HPLC water).
[0017] FIGS. 2A and 2B are autoradiographs that depict
.sup.125I-A.beta..sub.1-40 and .sup.125I-PUTA.beta..sub.1-40
labeling of amyloid deposits in vitro: AD temporal lobe sections
were incubated with .sup.125I-A.beta..sub.1-40 and exposed for 6
days (A) or with .sup.125I-PUT-A.beta..sub.1-40 and exposed for 1
day (B). Scale bars, 5 mm.
[0018] FIGS. 3A-3F are photomicrographs of
.sup.125I-A.beta..sub.1-40 and .sup.125I-PUT-A.beta..sub.1-40
labeling of amyloid deposits in vitro with equivalent
radioactivity. FIGS. 3A-3C represent adjacent sections incubated
with buffer alone (A), or 5.times.10.sup.5 cpm of either
.sup.125I-A.beta..sub.1-40 (B) or .sup.125I-PUT-A.beta..sub.1-40
(C) and processed for anti-A.beta. IH and emulsion autoradiography
with an equal exposure time of 6 days. Scale bars, 200 .mu.m. FIGS.
3D-3F are higher magnifications of amyloid deposits indicated by
arrows in FIGS. 3A-3C. Scale bars, 50 .mu.m.
[0019] FIGS. 4A-4F are photomicrographs of
.sup.125I-A.beta..sub.1-40 and .sup.125I-PUT-A.beta..sub.1-40
labeling of amyloid deposits in vitro with equivalent peptide
concentration. FIGS. 4A-4C represent adjacent sections incubated
with buffer alone (A), or 100 pM of either
.sup.125I-A.beta..sub.1-40 (B) or .sup.125I-PUT-A.beta..sub.1-40
(C) and processed for anti-A.beta. IH and emulsion autoradiography
with an equal exposure time of 6 days. Scale bars, 200 .mu.m. FIGS.
4D-4F represent higher magnification of amyloid deposits indicated
by arrows in FIGS. 4A-4C. Scale bars, 50 .mu.m.
[0020] FIGS. 5A-5H are photomicrographs of
.sup.125I-A.beta..sub.1-40 and .sup.125I-PUT-A.beta..sub.1-40
labeling of amyloid deposits in vitro in the absence or presence of
10-fold excess unbound putrescine. In FIGS. 5A and 5C, sections
were incubated with 100 pM of either .sup.125I-A.beta..sub.1-40
(5A) or .sup.125I-PUT-A.beta..sub.1-40 (5C) in the absence of
unbound putrescine. FIGS. 5B and 5D represent adjacent section
incubated with 100 pM of either .sup.125I-A.beta..sub.1-40 (5B) or
.sup.125I-PUT-A.beta..sub.1-40 (5D) in the presence of 10-fold
excess unbound putrescine. All sections were processed for
anti-A.beta. IH and emulsion autoradiography with an equal exposure
time of 6 days. Scale bars (5A-5D), 100 .mu.m. FIGS. 5E-5H
represent higher magnification of amyloid deposits indicated by
arrows in 5A-5D. Scale bars, 10 .mu.m.
[0021] FIGS. 6A-6D are photomicrographs of
.sup.125I-PUT-A.beta..sub.1-40 labeling of amyloid deposits in vivo
in APP, PS1 transgenic mouse brain. FIG. 6A is a section through
medial septum processed for anti-A.beta. IH and emulsion
autoradiography with 8 weeks of exposure exhibiting several labeled
deposits. FIG. 6B is an adjacent section showing the same deposits
stained with thioflavin S. FIGS. 6C and 6D represent higher
magnification of deposit #2. Scale bars (6A, 6B), 100 .mu.m; (6C,
6D), 10 .mu.m.
[0022] FIG. 7 is a pictorial representation of an NMR system used
to practice the present invention;
[0023] FIG. 8 is a graphic representation of a 3D gradient recalled
echo pulse sequence used to acquire image data according to a
preferred embodiment of the invention; and
[0024] FIG. 9 is a flow chart illustrating the steps for practicing
a preferred embodiment of the invention.
DETAILED DESCRIPTION
[0025] The invention features a method for detecting parenchymal
plaque deposits in the brain of a living mammal such as amyloid
deposits, neuritic plaques, and diffuse plaques. Amyloid deposits
include, for example, deposits of an A.beta. polypeptide or of a
prion protein (PrP). In some embodiments, the methods of the
invention can be used to detect tumors in the brain.
[0026] Applicants emphasize the importance of the cerebrovascular
versus parenchymal amyloid plaque deposition. Cerebrovascular
deposition initially occurs in the outer vessel wall of arteries
and capillaries more frequently than veins. These focal amyloid
deposits appear as clusters of delicate amyloid fibrils in the
abluminal membrane. In more affected vessels, the amyloid forms a
continuous ring within the vessel wall. As the pathology
progresses, amyloid fibrils can be observed extending continuously
from the endothelial cells into the neuropil.
[0027] In contrast, parenchymal amyloid plaque deposition occurs
within the brain tissue itself along a continuum that includes two
broad types of plaques: (1) diffuse plaques, in which A.beta.
accumulates largely in nonfilamentous extracellular deposits that
lack altered neurites and glia, and (2) neuritic plaques, in which
A.beta. accumulates principally in masses of extracellular
filaments closely associated with dystrophic dendrites and axons,
activated microglial, and reactive astrocytes.
[0028] It is important to realize that cerebrovascular deposition
of amyloid can be detected in 90% of AD patients; however,
cerebrovascular amyloid can occur in the absence of AD pathology
and vice versa. For example, patients with hereditary cerebral
hemorrhage with amyloidosis Dutch type, an autosomal-dominant
severe form of cerebral amyloid angiopathy caused by a point
mutation in the amyloid precursor protein, do not seem to develop
significantly more amyloid plaques or neurofibrillary tangles than
the normal elderly. Cerebrovascular amyloid also occurs as a
sporadic disorder evident in 30% of people over 60 years of age and
in 50% at age 90. The deposition of A.beta. in cerebral vessels
leads to severe vascular pathology and is a significant risk for
cerebral hemorrhage.
[0029] Methods of the invention include administering an amount of
a modified polypeptide to the mammal effective to detectably bind
to the extracellular deposits. The polypeptide has been modified to
enhance transmit through and exit from capillary endothelial cells
to the brain parenchyma. Suitable polypeptides have specific
binding affinity for the extracellular deposits and are at least 10
amino acid residues in length. For example, amyloid .beta. peptide
(A.beta.), which has affinity for amyloid deposits, can be used.
Non-limiting examples of A.beta. polypeptides that can be used
include A.beta..sub.1-40 and A.beta..sub.1-42 or derivatives
thereof. Beta-sheet blockers, i.e., short peptides that are
homologous to the central region of A.beta. and include residues
that inhibit beta-sheet formation (e.g., proline residues) can be
used, as well as peptidyl modulators of the recognition sequence of
.beta.-amyloid aggregation. Poduslo, et al., J. Neurobiol.,
39:371-382 (1999). Peptidyl modulators typically are peptides that
contain a portion of amino acid residues from the A.beta.
recognition sequence (within residues 15-25 of A.beta. and in
particular, residues KLVFF) and six lysine residues at the
C-terminus as a disrupting element. Pallito, et al., Biochemistry
38:3570-3578 (1999). For example, the peptidyl modulator can be a
peptide that includes residues 16-20 or 15-25 of A.beta. with 6
lysine residues at the C-terminus. Other derivatives of amyloid
precursor protein that have affinity for A.beta. plaques also are
suitable.
[0030] In addition, antibodies having specific binding affinity for
polypeptides within the extracelluar deposits (e.g., affinity for
A.beta..sub.1-40 or A.beta..sub.1-42, or the protease resistant
form of PrP) can be used. See, U.S. Pat. No. 5,231,000 and U.S.
Pat. No. 5,262,332 for examples of antibodies having specific
binding affinity for A.beta.. See, Zanusso, et al., Proc. Natl.
Acad. Sci. USA 95:8812-8816 (1998) for examples of antibodies
having specific binding affinity for the protease resistant form of
PrP. As used herein, antibodies include polyclonal or monoclonal
antibodies, humanized or chimeric antibodies, single chain Fv
antibody fragments, Fab fragments, and F(ab).sub.2 fragments.
Monoclonal antibodies are particularly useful. A chimeric antibody
is a molecule in which different portions are derived from
different animal species, such as those having a variable region
derived from a murine monoclonal antibody and a human
immunoglobulin constant region. Chimeric antibodies can be produced
through standard techniques.
[0031] Antibody fragments that have specific binding affinity for
A.beta..sub.1-40 and A.beta..sub.1-42 or for the protease resistant
form of PrP can be generated by known techniques. Such fragments
include, but are not limited to, F(ab').sub.2 fragments that can be
produced by pepsin digestion of the antibody molecule, and Fab
fragments that can be generated by reducing the disulfide bridges
of F(ab').sub.2 fragments. Alternatively, Fab expression libraries
can be constructed. See, for example, Huse, et al., Science
246:1275 (1989). Single chain Fv antibody fragments are formed by
linking the heavy and light chain fragments of the Fv region via an
amino acid bridge (e.g., 15 to 18 amino acids), resulting in a
single chain polypeptide. Single chain Fv antibody fragments can be
produced through standard techniques. See, for example, U.S. Pat.
No. 4,946,778.
[0032] Labeling and Polyamine Modification of Polypeptides
[0033] Polypeptides that are administered to the living mammal are
labeled and polyamine modified. The polypeptide has been modified
to enhance transmit through and exit from capillary endothelial
cells to the brain parenchyma. The use of a labeled peptide with
greater permeability across the capillary endothelid cells
increases sensitivity and allows the use of lower quantities of
radioisotope. Typical labels that are useful include radioisotopes
and contrast agents used for imaging procedures in humans.
Non-limiting examples of labels include radioisotope such as
.sup.123I (iodine), .sup.18F (fluorine), .sup.99mTc (technetium),
.sup.111In (indium), and .sup.67Ga (gallium), and contrast agents
such as, gadolinium (Gd), dysprosium, and iron. Radioactive Gd
isotopes (.sup.153Gd) also are available and suitable for imaging
procedures in non-human mammals. Polypeptides can be labeled
through standard techniques. For example, polypeptides can be
iodinated using chloramine T or
1,3,4,6-tetrachloro-3.alpha.,6.alpha.-diphenylglycouril. For
fluorination, polypeptides are synthesized and fluorine is added
during the synthesis by a fluoride ion displacement reaction. See,
Muller-Gartner, H., TIB Tech., 16:122-130 (1998) and Saji, H.,
Crit. Rev. Ther. Drug Carrier Syst., 16(2):209-244 (1999) for a
review of synthesis of proteins with such radioisotopes.
[0034] Polypeptides also can be labeled with a contrast agent
through standard techniques. For example, polypeptides can be
labeled with Gd by conjugating low molecular Gd chelates such as Gd
diethylene triamine pentaacetic acid (GdDTPA) or Gd
tetraazacyclododecanetetraacetic (GdDOTA) to the polypeptide. See,
Caravan, et al., Chem. Rev. 99:2293-2352 (1999) and Lauffer, et
al., J. Magn. Reson. Imaging 3:11-16 (1985). Antibodies can be
labeled with Gd by, for example, conjugating polylysine-Gd chelates
to the antibody. See, for example, Curtet, et al., Invest. Radiol.
33(10):752-761 (1998). Alternatively, antibodies can be labeled
with Gd by incubating paramagnetic polymerized liposomes that
include Gd chelator lipid with avidin and biotinylated antibody.
See, for example, Sipkins, et al., Nature Medicine, 4 623-626
(1998).
[0035] Polypeptides are modified with polyamines that are either
naturally-occurring or synthetic. See, for example, U.S. Pat. No.
5,670,477. Useful naturally-occurring polypeptides include
putrescine, spermidine, spermine, 1,3-diaminopropane,
norspermidine, syn-homospermidine, thermine, thermospermine,
caldopentamine, homocaldopentamine, and canavalmine. Putrescine,
spermidine, and spermine are particularly useful. Synthetic
polyamines are composed of the empirical formula
C.sub.xH.sub.yN.sub.z, and can be cyclic or acyclic, branched or
unbranched, hydrocarbyl chains of 3-12 carbon atoms that further
include 1-6 NR or N(R).sub.2 moieties, wherein R is H,
(C.sub.1-C.sub.4) alkyl, phenyl, or benzyl. Alternatively, amino
acids are synthesized with the appropriate polyamine (such as
Glu-4-aminobutane or Asp-4-aminobutane) and incorporated at the
appropriate sequence position during synthesis of the AB
derivative.
[0036] The permeability coefficient-surface area product (PS) at
the blood-brain barrier (BBB) is equivalent to the "permeability of
proteins at the BBB." The PS product (permeability) is a measure of
the rate of transport at the BBB. The BBB actually refers to tight
junctions that exist between the capillary endothelial cells which
prevent diffusion of reagents from the circulation into the brain
parenchyma. Unlike capillaries in other organs, brain capillaries
are unfenestrated (closed), whereas in most other organs the
capillaries are fenestrated (open); that is, windows exist between
the cells to allow for diffusion of reagents from circulation into
the tissue of the organ. Therefore, in order for a substance to
cross the BBB, it first must come in contact with the luminal
surface of the capillary endothelial cell and a mechanism must
exist by which this reagent is transported across this luminal
membrane (that is, by means of a receptor or transporter; see
Exhibit A). Once the reagent is in the endothelial cell, it must
undergo transcytosis and then exit from the endothelial cell at the
abluminal membrane surface by a different receptor or antiporter,
where it then passes into the brain parenchyma.
[0037] As described herein, putrescine modification of
A.beta..sub.1-40 significantly increased its permeability at the
blood brain barrier (BBB) an average of two-fold. Permeability at
the BBB of putrescine modified and Gd labeled A.beta..sub.1-40 also
was significantly increased 1.5-2.0 fold relative to native
A.beta..sub.1-40 It should be noted that the permeability
coefficient-surface area product (PS) values for A.beta..sub.1-40
are relatively high already and compare to that of insulin, whose
PS value in rat cortex is 15.78.times.10.sup.-6 ml/g/s, and BBB
uptake is known to occur by receptor-mediated transport. Poduslo,
J. F., et al., Proc. Natl. Acad. Sci. USA 9:5705-5709 (1994). As a
basis for comparison, the PS value for albumin in rat cortex is
0.15.times.10.sup.-6 ml/g/s, and is thought to cross the BBB by
passive diffusion. The high PS value for A.beta..sub.1-40 coupled
with stereospecific BBB permeability data for L-A.beta..sub.1-40
indicate that the BBB transport likely occurs by a
receptor-mediated mechanism. Thus, a doubling of the already high
PS value for A.beta..sub.1-40 by putrescine modification represents
a further dramatic increase in its permeability at the BBB with
important physiological implications for enhanced delivery into the
CNS.
[0038] There are many approaches for the chemical cross-linking or
"linkage" of polypeptides to polyamines. Significant advancement in
the application of these cross-linking agents has led to the
synthesis of cleavable bifunctional compounds. There are over 300
cross-linkers now available. It is desirable that the linkage of
polypeptide to polyamine allows the polypeptide to maintain the
ability to bind the extracellular deposit and the polyamine to
facilitate increased permeability at the BBB.
[0039] Numerous considerations, such as reactivity, specificity,
spacer arm length, membrane permeability, cleavability and
solubility characteristics need to be evaluated when choosing an
appropriate cross-linker. See, for example, "Chemistry of Protein
Conjugation and Cross-Linking", Shan S. Wong, CRC Press, Ann Arbor,
1991. Functional groups that are available for conjugation are not
involved in the binding of the polypeptide to the extracellular
deposit.
[0040] Linking reagents have at least two reactive groups and can
be either homobifunctional with two identical reactive groups or
heterobifunctional with two or more different reactive groups.
Trifunctional groups also exist and can contain three functional
groups. Most homobifunctional cross-linkers react with primary
amines commonly found on proteins. Other homobifunctional
cross-linkers couple through primary sulfhydryls. Homobifunctional
cross-linkers can be used in a one step reaction procedure in which
the compounds to be coupled are mixed and the cross-linker is added
to the solution. The resulting cross-linking method may result in
self-conjugation, intermolecular cross-linking, and/or
polymerization. The following are examples of cross-linking
approaches and are not meant to be inclusive.
[0041] Imido esters are the most specific acylating reagents for
reaction with amine groups whereby in mild alkaline pH, imido
esters react only with primary amines to form imidoamides. The
product carries a positive charge at physiological pH, as does the
primary amine it replaces and therefore, does not affect the
overall charge of the protein.
[0042] Homobifunctional N-hydroxysuccinimidyl ester conjugation is
also a useful cross-link approach to crosslink amine-containing
proteins. Homobifunctional sulfhydryl reactive cross-linkers
include bismaleimidhexane (BMH), 1,5-difluoro-2,4-dinitrobenzene
(DFDNB), and 1,4-di-(3',2'-pyridyldithio) propionamido butane
(DPDPB).
[0043] Many heterobifunctional cross-linkers are commercially
available with the majority containing an amine-reactive functional
group on one end and a sulfhydryl-reactive group on the other end.
Multiple heterobifunctional haloacetyl cross-linkers are available,
as are pyridyl disulfide cross-linkers. Carbodiimides are a classic
example of heterobifunctional cross-linking reagents for coupling
carboxyls to amines resulting in an amide bond.
[0044] Administration of Labeled, Polyamine Modified
Polypeptides
[0045] The labeled, polyamine modified polypeptides are formulated
with a pharmaceutically acceptable carrier and administered to the
living mammal. In general, the polypeptides are administered
intravenously (i.v.), although other parenteral routes of
administration, including subcutaneous, intramuscular,
intrarterial, intracarotid, and intrathecal also can be used.
[0046] Formulations for parenteral administration may contain
pharmaceutically acceptable carriers such as sterile water or
saline, polyalkylene glycols such as polyethylene glycol, vegetable
oils, hydrogenated naphthalenes, and the like.
[0047] The dosage of labeled, polyamine modified polypeptide to be
administered will be determined by the attending physician taking
into account various factors known to modify the action of drugs.
These include health status, body weight, sex, diet, time and route
of administration, other medications, and any other relevant
clinical factors. Typically, about 1-3000 .mu.g/kg body weight are
administered. For example, the dosage can range from about 10-1000
.mu.g/kg body weight or 50-500 .mu.g/kg body weight.
Therapeutically effective dosages may be determined by either in
vitro or in vivo methods.
[0048] Detecting Polypeptides Bound to Extracellular Deposits
[0049] Imaging techniques that can be used to detect labeled
deposits include positron emission tomography (PET),
gamma-scintigraphy, magnetic resonance imaging (MRI), functional
magnetic resonance imaging (FMRI), magnetoencephalography (MEG),
and single photon emission computerized tomography (SPECT). Such
imaging techniques can be used to detect labeled deposits in vitro
or in vivo.
[0050] MRI is a particularly useful imaging technique, as the
spatial resolution (e.g., 30 microns) and signal-to-noise ratio
provided by MRI are suitable for detecting amyloid deposits in a
sample. Any type of MRI data set can be acquired from a sample,
including T1 or T2 images (e.g., a T1-weighted (T1W) or T2-weighted
(T2W) image). Areas that contain plaques can be visualized in bulk
relative to a control region of the brain. That is, instead of
looking at individual plaques, regions of the brain that typically
contain plaques can be examined as a whole. Areas in the brain of
AD patients that typically contain plaques include the limbic
cortex and heteromodal association cortices. Areas in the brain of
an AD patient that typically remain free of plaque deposition can
be used as control regions. Such regions include the cerebellum,
the primary occipital cortex, and the primary sensory motor cortex.
To detect plaques, the average signal intensity of each region can
be compared. For example, T1 images of the limbic cortex and
cerebellum can be obtained and the average signal intensity
determined for each region. An increase in signal intensity in the
limbic cortex relative to that in the cerebellum would indicate
that plaques are present. Comparing the signal intensities of the
two regions provides a useful measure of regional plaque density,
plaque distribution within the bulk tissue, as well as Alzheimer's
disease progression within the patient.
[0051] Individual labeled deposits also can be detected by
comparing the signal intensity of a region bounding a suspected
plaque relative to that of a region adjacent to the plaque. With a
T2 weighted image, the average signal intensity of a labeled plaque
is typically reduced relative to the average signal intensity in a
region adjacent to the plaque. With a T1 weighted image, the
average signal intensity of a labeled plaque is typically elevated
when compared to average signal intensity in a region adjacent to
the plaque.
[0052] It is understood that parameters such as voxel size and
magnetic field strength can be optimized when detecting
extracellular deposits using MRI. Additional parameters and methods
of optimization are known in the art. For example, a voxel volume
of 1.25.times.10.sup.5 to 1.0.times.10.sup.6 cubic microns (i.e.,
1.25.times.10.sup.5, 1.5.times.10.sup.5, 2.0.times.10.sup.5,
5.0.times.10.sup.5, or 1.0.times.10.sup.6 cubic microns) and a high
magnetic field strength (e.g., 7 tesla or greater) can be used to
improve the resolution and detection of individual labeled plaques
in the brain in vivo. Motion correction techniques also can be used
to further improve data sets obtained using in vivo MRI.
[0053] Referring to FIG. 7, an MRI magnet assembly 10 has a
cylindrical bore tube 12 extending along a z-axis 13 for receiving
a supine patient 14 supported on a table 16. The table 16 may move
in and out of the bore tube 12 so as to position the patient 14
along the z-axis 13 within the volume of the bore tube 12.
[0054] Coaxially surrounding the bore tube 12 is a whole-body RF
coil 18 for exciting the spins of the patient 14 into resonance.
Whole-body gradient coils 20 surround both the bore tube 12 and the
RF coil 18 and are also coaxial with the z-axis 13, to provide x, y
and z gradient fields G.sub.x, G.sub.y and G.sub.z as required for
MRI imaging. The gradient coils 20 are driven by gradient
amplifiers (not shown). The polarizing magnetic field B.sub.0,
aligned with the z-axis 13 is generated by a superconducting magnet
coil 28 coaxial with but outside the bore tube 12, the RF coil 18
and the gradient coils 20. The superconducting magnet coil 28 has
no external power supply but operates on an initial current which
continues unabated in the zero resistivity windings of the
superconducting magnet coil 28.
[0055] Interposed between the superconducting magnet coil 28 and
the gradient coil 20 is a set of shim coils 30 which are used to
correct the homogeneity of the polarizing field B.sub.0 as is
understood in the art. A set of mechanical linkages and insulators
(not shown) rigidly connect each of these coils 18, 20, 28 and 30
together to the bore tube 12 so as to resist relative motions
generated by the interaction of their various electromagnetic
fields.
[0056] When a local coil assembly 8 is used in a general purpose
system such as that described above, the whole-body gradient coils
20 and whole-body RF coil 18 are disconnected. The local coil
assembly 8 is connected to the x, y and z gradient amplifiers (not
shown) on the NMR system and it is connected to the system's
transceiver through a transmit/receive switch. The preferred
embodiment employs a 3 Tesla MRI system manufactured by Bruker
Analytische MeBtechnik GmbH and sold under the trademark BIOSPEC
30/60.
[0057] Because the gradient fields are switched at a very high
speed to practice the preferred embodiment of the invention, local
gradient coils are employed in place of the whole-body gradient
coils 139. These local gradient coils are designed for the head and
are in close proximity thereto. This enables the inductance of the
local gradient coils to be reduced and the gradient switching rates
increased. The local gradient coil assembly 8 also includes a local
brain RF coil. In the preferred embodiment, it is a 16 element
bandpass endcapped birdcage coil. This brain RF coil is designed to
couple very efficiently to the brain of the subject and less
efficiently to the lower part of the head. This results in improved
brain image quality compared with larger general purpose head coils
that couple uniformly to the entire head as well as the neck. An RF
shield surrounds the local brain coil and interior to the local
gradient coil. This shield isolates RF radiation from the local
gradient coil. The shield is designed to avoid perturbation of time
varying gradient fields. For a description of these local gradient
coils and the RF coil which is incorporated herein by reference,
reference is made to U.S. Pat. No. 5,372,137 filed on Jan. 19, 1993
and entitled "NMR Local Coil For Brain Imaging".
[0058] The MRI system of FIG. 7 performs a series of pulse
sequences to collect sufficient NMR image data to reconstruct an
image. Referring particularly to FIG. 8, an exemplary pulse
sequence for conducting a 3DFT NMR scan is shown. The pulse
sequence commences by the selective excitation of the entire region
of interest with an RF excitation pulse 25 in the presence of a
slab select G.sub.z gradient pulse 26. The frequency content of the
excitation pulse 25 and the amplitude of the slab select Gz pulse
26 are selected to produce transverse magnetization in the region
of the subject's brain which is the subject of the 3D scan. A
negative Gz pulse 27 is then produced to rephase the spins in
preparation for the phase encoding and readout.
[0059] Phase encoding is performed along two axes: the z-axis and
the y-axis. The z-axis encoding is accomplished by applying a
G.sub.z phase encoding pulse 28 and the y-axis encoding is
accomplished by applying a G.sub.y phase encoding pulse 29. As is
well-known to those skilled in the art, the magnitude of the phase
encoding pulses 28 and 29 are stepped through a series of positive
and negative values during the scan, but each is set to one value
during each pulse sequence.
[0060] After phase encoding the transverse magnetization, the NMR
signal 30 is read-out and acquired in the presence of a G.sub.x
read-out gradient 31. This read-out is preceded by a negative
G.sub.x gradient pulse 32 to produce the gradient refocused NMR
echo signal 30 in the usual fashion. The 3DFT pulse sequence is
then concluded by the application of a large G.sub.z spoiler
gradient pulse 33 and a G.sub.y rewinder gradient pulse 34 to
prepare the magnetization for the next pulse sequence which
follows. As is known to those skilled in the art, the spoiler pulse
33 dephases transverse magnetization and the rewinder pulse 34
refocuses transverse magnetization along the y-axis in preparation
for the next pulse sequence. The rewinder pulse 34 is equal in
magnitude, but opposite in polarity with the G.sub.y phase encoding
pulse 29. The scan parameters of the pulse sequence are selected to
acquire a very high resolution (e.g., 1 mm cubic voxels) T1
weighted image of a selected 3D volume of the subject's brain.
[0061] Contrast enhanced examinations are performed routinely in
clinical brain MRI studies. The agents used are biologically stable
gadolinium chelates such as gadolinium
diethylenetriaminepentaacetic acid (Gd-DTPA). The NMR signal 30
acquired by the pulse sequence is produced by water protons, or
"spins" which are omnipresent in the tissue. Gd-DTPA accelerates
the T1 relaxation rate of nearby spins in direct proportion to its
concentration in tissue. In concentrations used in clinical
studies, the T1 acceleration effort of Gd-DTPA is substantially
more pronounced than T2 acceleration. The basis for visualization
of .beta.-amyloid plaques using contrast enhanced MRI is the
acceleration of the T1 relaxation rate of tissue water protons in
the vicinity of .beta.-amyloid plaques that have been specifically
targeted by the gadolinium tagged molecular probe.
[0062] The ideal MRI contrast agent for visualizing and quantifying
the pathologic burden of .beta.-amyloid plaque has four properties:
1) it is highly stable in vivo, 2) it crosses the BBB
nondestructively following intravenous injection, 3) it binds to
parenchymal amyloid plaques with high affinity, and 4) it produces
local changes in tissue contrast detectable by MRI. We have
demonstrated that these properties exist in
putrescine-gadolinium-amyloid-.beta. peptide (PUT-Gd-A.beta.).
[0063] Referring particularly to FIG. 9, the imaging method
according to a preferred embodiment of the invention includes the
acquisition of a reference image as indicated at process block 50.
This employs the MRI system of FIG. 7 and the pulse sequence of
FIG. 8. The scan parameters are identical to those to be used in
subsequent contrast enhanced image acquisition. The purpose of this
reference acquisition is to produce an image that is not contrast
enhanced. As indicated at process block 52, the subject is then
injected with a contrast agent. This is done using a GdDTPA
contrast agent conjugated to a polypeptide and modified with
polyamines as described in detail above.
[0064] As indicated at process block 54, a substantial waiting
period is then required before the procedure can continue. During
this waiting period the contrast agent penetrates the BBB as
described above and binds to parenchymal amyloid plaques in the
brain. The contrast agent remains bound to plaque for many hours
and a waiting period is required to dissipate the unbound contrast
agent which is flowing throughout the subject's vasculature. This
is substantially different from prior contrast enhanced MRI brain
studies where image acquisitions are timed for peak contrast agent
concentration in the vasculature. In the present method sufficient
time must be allowed to pass such that signals from untargeted
spins are no longer significantly enhanced by the contrast
agent.
[0065] The lengthy waiting period usually requires that the subject
be removed from the MRI system for a period of time. When the
waiting period is over, the subject is placed back in the MRI
system and aligned in the exact same position and orientation with
respect to the MRI system imaging gradient coordinates as indicated
at process block 56. While this can be done with a great deal of
precision by physically aligning the subject, because very high
resolution images are being acquired, a more precise alignment
method is preferred. More particularly, a spherical 3D reference
navigator signal is acquired with the reference image data set and
another spherical 3D navigator signal is now acquired after the
subject is repositioned. As described in co-pending U.S. patent
application (MMV-01-160) filed on Dec. 19, 2002 and entitled
"Alignment Of Multiple MR Images Using Navigator Signals" the MRI
imaging gradient coordinates are rotated and translated as
necessary to precisely register subsequently acquired images with
previously acquired reference images.
[0066] As indicated at process block 58, after the subject is
properly aligned, a contrast enhanced image data set is acquired
using the pulse sequence in FIG. 8. The scan parameters are
identical to those used to acquire the reference image data set.
Both 3D image data sets are then Fourier transformed along each of
their three axes and two corresponding magnitude images are
produced as indicated at process block 60. The 3D reference
magnitude image indicates pre-contrast NMR signal strength at each
of its pixels, and the 3D contrast enhance magnitude image
indicates NMR signal strength at corresponding pixels after the
contrast agent has bound to plaques.
[0067] As indicated at process block 62, the reference magnitude
image is then subtracted on a pixel-by-pixel basis from the
contrast enhanced magnitude. The resulting difference image
indicates the location and magnitude of signal enhancement due to
contrast agent. Since the targeted contrast agent only binds to
plaques, the difference image indicates the location of bulk tissue
enhancement due to plaques in the 1 mm cubic voxel that corresponds
to the 3D image pixels.
[0068] To confirm that the targeted contrast agent only binds to
plaques and that the difference in image intensity corresponds to
plaque locations, a number of experiments have been performed as
described in the examples below.
[0069] MRI was performed at a magnetic field strength of 7 Tesla
with a Bruker Avance DRX-300, 89-mm vertical bore spectrometer at
an ambient temperature of 22.degree. C. The glass tube containing
embedded mouse brain was placed into a 10 mm diameter RF coil.
T1-weighted (T1W) and T2-weighted (T2W) imaging sequences were
performed with the following parameters: field of view of 1.6 cm
along the z (vertical magnet) axis and 0.8 cm along the other two
orthogonal axes; data acquisition matrix size of 256 (along the z
axis).times.128.times.128 resulting in cubic voxels 62.5 .mu.m in
all dimensions. The signal was read along the z-axis direction at a
bandwidth of 50 kHz. A T2W image volume with TR=3000 ms and TE=100
ms was obtained in 13 hours, 52 minutes. A T1W image volume with
TR=400 ms and TE=8 ms and 8 signal averages was obtained in 14
hours, 42 minutes.
[0070] Histological correlation was performed following MRI.
Briefly, the bottom of the glass MRI tube was cut off and the
hemisphere-containing agar extruded. The agar was then carefully
cut away from the hemisphere. A 5 mm thick block of agar was left
attached to the posterior of the hemisphere as a base for mounting
to the microtome platform to maintain the same orientation of the
hemisphere as in the MRI scan. After cryoprotecting in sucrose,
frozen coronal sections (30 .mu.m) of each hemisphere were cut with
a sliding microtome throughout the entire cerebral cortex. All
sections were saved and stored at 4.degree. C. in a PBS solution
containing 2 mM sodium azide until mounted. Every other section was
mounted on gelatin-subbed slides and dried overnight at 37.degree.
C. The dried sections were stained with fresh, filtered, aqueous 1%
thioflavin S, a fluorescent dye that stains neuritic-type
.beta.-amyloid plaques. The thioflavin S-positive .beta.-amyloid
deposits were visualized in the sections using a confocal laser
scanning microscope (Zeiss LSM 310) equipped with a 2.5.times.
objective at a zoom setting of 0.8 to fit the entire section of
hemisphere within the field of view. Confocal images were obtained
using an argon/krypton laser and settings for fluorescein
isothiocyanate (FITC) at an excitation wavelength of 488 nm and
emission of 520 nm. Images were saved as digitized TIFF files to
retain maximum resolution. Images of the individual histologic
sections were combined to create a digitized three-dimensional (3D)
volume of the specimen using ANALYZE image analysis software
version. See, for example, Robb, R. A., in "3D Imaging in
Medicine", K. H. Hohne, S. M. Pizer, Eds. (NATO ASI Series, 1990)
pp. 333-361. The 3D T2W MRI volume was then spatially matched to
the digitized histologic volume using common anatomic landmarks,
e.g., the anterior commissure. The rigid-body transformation matrix
derived from the anatomic matching procedure was saved and applied
to both the T2W and T1W MRI volumes, which were resampled in the
space of the digitized histologic volume using sinc interpolation.
The T2W and T1W MRI volumes were in perfect spatial registration
with each other a priori because the geometric parameters of the
T1W and T2W acquisition protocols were identical.
EXAMPLES
Example 1
PS and V.sub.p Measurements of Radioiodinated A.beta. Proteins
[0071] Permeability of A.beta..sub.1-40 or PUT-A.beta..sub.1-40 at
the BBB was determined using an i.v. bolus injection technique that
has been described in detail. Poduslo, J. F. and Curran, G. L.,
Proc. Natl. Acad. Sci. USA 89:2218-2222 (1992); Poduslo, J. F. and
Curran, G. L., Molec. Brain Res. 23:157-162 (1994); and Poduslo, J.
F., et al., Proc. Natl. Acad. Sci. USA 9:5705-5709 (1994).
Putrescine modification of synthetic human A.beta..sub.1-40 was
performed by covalent linkage of the polyamine to carboxylic acid
groups using carbodiimide at a pH of 6.7. Poduslo, J. F. and
Curran, G. L., J. Neurochem. 66:1599-1609 (1996); and Poduslo, J.
F. and Curran, G. L., J. Neurochem. 67:734-741 (1996).
[0072] Separate aliquots of native (A.beta. 1-40) or
putrescine-modified (PUT-A.beta. 1-40) peptides then were labeled
with .sup.125I and .sup.131I (Amersham) using a modified
chloramine-T procedure. PS and V.sub.p values were determined in
normal adult male Sprague-Dawley rats (400-450 g) obtained from
Harlan. All procedures performed were in accordance with NIH
Guidelines for the Care and Use of Laboratory Animals. Briefly, a
bolus of 0.9% NaCl containing A.beta..sub.1-40 or
PUT-A.beta..sub.1-40 labeled with .sup.125I was injected rapidly
into the catheterized brachial vein of an anesthetized rat (sodium
pentobarbital, 25 mg/kg, i.p.). Blood (200 .mu.l) was sampled from
the brachial artery at several intervals during the next 15
minutes. An aliquot of the peptide labeled with .sup.131I was then
injected into the brachial vein 15 seconds prior to sacrifice of
the animal to serve as a measure of residual plasma volume
(V.sub.p; .mu.l/g). After collection of the final blood sample, the
anesthetized animal was sacrificed. Several brain regions and
plasma samples were assayed for .sup.125I and .sup.131I
radioactivity in a two-channel gamma counter (Cobra II, Packard)
with the activity corrected for background and crossover of
.sup.131I activity into the .sup.125I channel. The permeability
coefficient x surface area products (PS; 10.sup.-6 ml/g/s) for
A.beta..sub.1-40 and PUT-A.beta..sub.1-40 were calculated using the
V.sub.p (.mu.l/g) as a measure of residual plasma volume.
Statistical evaluations of PS and V.sub.p were performed using
ANOVA followed by Bonferroni multiple comparisons.
[0073] Putrescine-modified A.beta..sub.1-40 (PUT-A.beta..sub.1-40)
exhibited increased permeability at the BBB compared to native
A.beta..sub.1-40. Putrescine modification significantly increased
the BBB permeability of PUT-A.beta..sub.1-40 in all brain regions
measured, compared to A.beta.1-40, with significant increases in
the permeability coefficient x surface area product (PS) ranging
from 1.9-fold in the hippocampus and cerebellum to 2.3-fold in the
cortex and thalamus (Table 1). The residual plasma volume (V.sub.p)
was increased slightly, but significantly in three of six brain
regions (Table 1). This was probably a result of the large
increases in the PS values observed for PUT-A.beta..sub.1-40, with
some of the peptide crossing the BBB even in the short time used in
this experiment for the administration of the second isotope (15
seconds).
TABLE-US-00001 TABLE 1 PS and Vp of A.beta..sub.1-40 and PUT
A.beta..sub.1-40 PS Vp Brain Region A.beta. 1-40 PUT A.beta. 1-40
RI A.beta. 1-40 PUT A.beta. 1-40 RI Cortex 10.9 .+-. 0.6 25.5 .+-.
3.2 2.3*** 9.4 .+-. 0.4 13.9 .+-. 0.7 1.5** Caudoputamen 12.8 .+-.
0.7 26.0 .+-. 3.4 2.0*** 6.6 .+-. 0.4 9.2 .+-. 0.8 1.4**
Hippocampus 12.7 .+-. 1.4 24.3 .+-. 2.9 1.9*** 8.6 .+-. 1.4 10.1
.+-. 0.5 1.2 Thalamus 13.4 .+-. 0.7 30.2 .+-. 3.2 2.3*** 12.2 .+-.
0.6 11.1 .+-. 0.3 0.9 Brain Stem 17.7 .+-. 1.2 35.1 .+-. 5.3 2.0***
16.2 .+-. 1.2 25.5 .+-. 1.7 1.6*** Cerebellum 18.2 .+-. 1.5 34.8
.+-. 4.1 1.9*** 12.4 .+-. 0.8 15.1 .+-. 0.8 1.2 PS is the
permeability coefficient x surface area product (mean .+-. SEM
.times. 10.sup.-6 ml/g/s; n = 10). Vp is the residual plasma volume
(mean .+-. SEM .mu.l/g; n = 10). RI is the relative increase of PUT
A.beta..sub.1-40 compared to A.beta..sub.1-40. *p < 0.05, **p
< 0.01, ***p < 0.001.
Example 2
Labeling of Amyloid Plaques In Vitro
[0074] The next step was to determine if PUT-A.beta..sub.1-40 would
bind and label amyloid deposits in AD brain sections in vitro.
A.beta..sub.1-40 and PUT-A.beta..sub.1-40 were first radiolabeled
with .sup.125I to facilitate detection and then purified to remove
unbound .sup.125I and unlabeled peptide. Radioiodinated
A.beta..sub.1-40 and PUT-A.beta..sub.1-40 were purified using
reversed-phase high performance liquid chromatography (RP-HPLC) to
remove iodotyrosine and unlabeled peptide in order to achieve very
high specific activity. Maggio, J. E., et al., Proc. Natl. Acad.
Sci. USA 89:5462-5466 (1992); and Ghilardi, J. R., et al.,
NeuroReport 7:2607-2611 (1996). Following radioiodination, the
peptides were dialyzed for 4 hours against 0.2 M NaI to remove
unbound .sup.125I. The peptides were then passed over a C.sub.18
preparative cartridge (Sep-Pak Light, Waters Corp.) to remove more
unbound .sup.125I. The peptide was eluted stepwise with increasing
concentrations of acetonitrile (ACN) in 0.05% trifluoroacetic acid
(TFA) (10, 20, 40, 80, 100% ACN, Fisher). The peptides eluted
primarily in the 40 and 80% ACN fractions and were reduced by
adding 2-mercaptoethanol (2-ME, BioRad). The peptides were
concentrated to 0.25 ml with a Speed Vac (Savant).
[0075] The .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40 were purified by RP-HPLC (System
Gold, Beckman) using a gradient method with a binary solvent system
(Buffer A: 0.05% TFA/99.95% water; Buffer B: 80% ACN/0.05%
TFA/19.95% water). Each peptide was injected and purified using a
1-hour gradient of 0-100% Buffer B at a rate of 1 ml/min using a
small-bore, C.sub.18 column (5 .mu.m, 4.6.times.250 mm, #218TP54,
Vydac). Chromatograms of HPLC elution profiles of unlabeled
A.beta..sub.1-40 and PUT-A.beta..sub.1-40 are shown in FIGS. 1A and
1B, respectively. PUT-A.beta..sub.1-40 elutes earlier than
A.beta..sub.1-40 because the positively charged amine groups of
putrescine make PUT-A.beta..sub.1-40 less hydrophobic. One-minute
(1 ml) fractions were collected with the detector turned off so as
not to quench any of the radioactivity. Aliquots (5 .mu.l) of ten
fractions surrounding the most radioactive fraction were then
counted with the gamma counter to identify the fraction with the
highest radioactivity. That fraction containing the purest
.sup.125I-labeled peptide was then concentrated to 0.25 ml with a
Speed Vac to remove the ACN and stored at -20.degree. C. in the
presence of a reducing agent (2-ME). Aliquots of the RP-HPLC
fractions presumed to contain the .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40 were analyzed by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE). Only a single band was observed for
all fractions of .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40, verifying their purity.
[0076] HPLC purified .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40 were incubated with adjacent
sections of unfixed AD temporal lobe cortex. Three adjacent
sections were incubated with either .sup.125I-A.beta. 1-40,
.sup.125I-PUT-A.beta. 1-40, or vehicle. Briefly, the sections were
first blocked with 0.1% bovine serum albumin (BSA) in 0.05 M Tris
HCl/0.9% NaCl (TBS), pH 7.0 for 30 minutes. The sections were then
incubated for 3 hours with 100 .mu.M .sup.125I-A.beta..sub.1-40 or
.sup.125I-PUT-A.beta.1-40, or alone in 250 .mu.l of TBS, pH 7.0
containing 0.1% BSA, 0.6 mg/ml magnesium chloride, 0.04 mg/ml
bacitracin, 0.002 mg/ml chymostatin, and 0.004 mg/ml leupeptin. The
sections were washed with TBS, pH 7.0 four times and then rinsed
briefly with distilled water twice. The sections were allowed to
air dry overnight in a box with desiccant at 4.degree. C.
[0077] Sections then underwent immunohistochemistry (IH) for
amyloid using an anti-AP monoclonal mouse antibody (4G8, Senetek).
Untreated sections were included as a positive control for antibody
staining. After rehydrating with TBS, pH 7.6, the sections were
fixed briefly with neutral-buffered, 10% formal in for 3 minutes.
The sections were washed with TBS and then blocked with 1.5% normal
horse serum in TBS for 30 minutes. The sections were incubated with
the anti-A.beta. primary antibody at a dilution of 1:1000 in 0.1%
BSA/TBS overnight at 4.degree. C. The primary antibody was then
visualized using a Vectastain Elite ABC, immunoperoxidase kit with
diaminobenzidine (DAB) as a substrate according to the instructions
(Vector Laboratories). The sections were allowed to air dry
overnight in a box with desiccant at 4.degree. C.
[0078] Following immunohistochemistry (IH) to visualize the amyloid
deposits, the sections were subjected to film and emulsion
autoradiography to detect the presence of the
.sup.125I-A.beta..sub.1-40 or .sup.125I-PUT-A.beta..sub.1-40. The
sections were exposed to high-resolution autoradiographic film
(Hyperfilm MP, Amersham) at -70.degree. C. to visualize
.sup.125I-labeled amyloid deposits. FIGS. 2A-2B are the film
autoradiographs. Note the presence of punctate areas of exposed
film located predominantly in the regions corresponding to gray
matter. This is similar to the distribution of amyloid deposits
seen following IH of the tissue sections. It was possible to
overlay the two for direct correspondence under the microscope. A
longer duration of exposure was required for
.sup.125I-A.beta..sub.1-40 (6 days) to achieve equal relative
intensity as .sup.125I-PUT-A.beta..sub.1-40 (1 day), suggesting
that .sup.125I-PUT-A.beta..sub.1-40 may have greater affinity to
the amyloid deposits than .sup.125I-A.beta..sub.1-40.
[0079] In order to definitively correlate the IH with the iodinated
peptide by colocalization, the sections were next dipped in an
autoradiographic emulsion (Type NTB-3, Kodak). The slides were
dipped in emulsion at 43.degree. C. under Safelight illumination in
a darkroom. The slides were chilled to solidify the emulsion and
then allowed to air dry at room temperature for 3 hours in a
light-proof box. The slides were exposed at 4.degree. C. in a
light-proof box with desiccant. The slides were developed with
Dektol developer (Kodak) and fixed (Kodak) according to the
instructions. The sections were dehydrated with successive changes
of ethanol and xylene and then coverslipped with a xylene-based
mounting media (CMS).
[0080] The presence of the iodinated peptide was revealed by
exposed (blackened) silver grains directly on the same tissue
previously stained with anti-AP antibody. These results are
illustrated in the photomicrographs of FIGS. 3-5. FIGS. 3A-3F
illustrate the binding of equal amounts of radioactivity of
.sup.125I-A.beta..sub.1-40 and .sup.125I-PUT-A.beta..sub.1-40 to
amyloid deposits in adjacent sections of AD temporal lobe cortex in
vitro. All sections were processed for anti-A.beta. IH and emulsion
autoradiography with an equal exposure time of 6 days. The amyloid
deposits appear brown. The presence of iodinated peptide is
indicated by increased density of black, exposed silver grains. The
binding of both peptides is specific to the amyloid deposits due to
the low density of exposed silver grains in the background.
Furthermore, it seems to be selective for the dense-core,
neuritic-type plaques on the left than the diffuse plaque located
on the right (FIGS. 3E, F). Also note that with equal amounts of
radioactivity and exposure time there is a higher density of silver
grains for .sup.125I-PUT-A.beta..sub.1-40, suggesting that the
modified peptide has a greater affinity for the neuritic plaques
than .sup.125I-A.beta..sub.1-40. FIGS. 4A-4F illustrate the binding
of equal peptide concentrations of .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40 to amyloid deposits in adjacent
sections of AD temporal lobe cortex in vitro. These results are
similar to FIGS. 3A-3F.
[0081] Based on the result that .sup.125I-PUT-A.beta..sub.1-40 has
a greater affinity for neuritic plaques than
.sup.125I-A.beta..sub.1-40, an experiment was performed to
determine the effect of putrescine on binding by incubating the
peptides in the absence or presence of excess unbound putrescine.
If putrescine also binds to amyloid, then one might expect to see
decreased binding of iodinated peptide in a competitive manner in
the presence of excess unbound putrescine. FIGS. 5A-5H illustrate
the binding of .sup.125I-A.beta..sub.1-40 and
.sup.125I-PUT-A.beta..sub.1-40 to amyloid deposits in AD temporal
lobe cortex in vitro in the absence or presence of a 10-fold excess
of unbound putrescine. There appears to be no appreciable effect on
binding of iodinated peptide in the presence of unbound putrescine,
even at 10-fold excess. This suggests that putrescine itself does
not bind specifically to amyloid, but may enhance binding by some
other mechanism.
[0082] In summary, in addition to increased permeability at the
BBB, .sup.125I-PUT-A.beta..sub.1-40 also labeled amyloid deposits
in vitro with greater affinity than .sup.125I-A.beta..sub.1-40,
based on shorter exposure times or increased intensity of
autoradiography emulsion. There is not a clear explanation for this
observation as the addition of ten-fold excess of unbound
putrescine did not decrease labeling in a competitive manner. In
fact, because amyloid is highly hydrophobic and
PUT-A.beta..sub.1-40 appears to be relatively less hydrophobic than
A.beta..sub.1-40, based on a shorter retention time during HPLC,
one might expect to observe decreased labeling with
.sup.125I-PUT-A.beta..sub.1-40. Furthermore, the addition of
putrescine to the structure of A.beta..sub.1-40 could possibly
block binding sites and also reduce labeling. The binding of both
PUT-A.beta..sub.1-40 and A.beta..sub.1-40, however, appeared to be
specific for dense-core, neuritic-type amyloid deposits, since no
diffuse deposits were labeled and background labeling was not
noticeable.
Example 3
Labeling of Amyloid Plaques In Vivo
[0083] .sup.125I-PUT-A.beta..sub.1-40 was then tested for its
ability to cross the BBB and label amyloid deposits in vivo
following i.v. injection in transgenic mice that express two mutant
human proteins associated with familial AD. These mice develop
amyloid deposits and behavioral deficits within 12 weeks of age.
Hemizygous transgenic mice (Tg2576) expressing mutant human amyloid
precursor protein (APP.sub.695) were mated with a second strain of
hemizygous transgenic mice (M146L5.1) expressing mutant human
presenilin 1 (PS1). Holcomb, L., et al., Nature Med. 4:97-100
(1998). The animals were genotyped for the expression of both
transgenes by a dot blot method using a sample of mouse tail DNA.
The mice were housed in a virus-free barrier facility under a
12-hour light/dark cycle, with ad lib access to food and water. All
procedures performed were in accordance with NIH Guidelines for the
Care and Use of Laboratory Animals. Quantitative histological
analyses of amyloid deposition indicate that deposition of
neuritic-type plaques occurs at a rapid rate starting around 12
weeks, reaching an amyloid burden of over 3.5% in cortex and
hippocampus in one year.
[0084] These APP, PS1 transgenic mice (27 weeks of age) were
catheterized in the femoral vein under general anesthesia (sodium
pentobarbital, 25 mg/kg, i.p.) and injected with 200 .mu.g of
.sup.125I-A.beta..sub.1-40 or .sup.125I-PUT-A.beta..sub.1-40. One
mouse was injected with .sup.125I-A.beta..sub.1-40 and two with
.sup.125I-PUT-A.beta.1-40. After four hours, each animal was
perfused with PBS and fixed with neutral-buffered, 10% formalin
following an overdose with sodium pentobarbital (75 mg/kg, i.p.).
After cryoprotecting in 10% and 30% sucrose in PBS, frozen sections
of each brain were cut with a freezing microtome and then processed
with anti-AP IH and emulsion autoradiography for the presence of
radiolabeled amyloid deposits using the same methods described
above for the human AD sections.
[0085] The results are shown in FIG. 6. FIG. 6A a photomicrograph
of a section through the medial septum that exhibits several
parenchymal amyloid deposits radiolabeled with
.sup.125I-PUT-A.beta..sub.1-40. This particular section was exposed
for 8 weeks, but labeled deposits could be observed after only one
week of exposure. FIG. 6C illustrates a higher magnification of one
of the parenchymal deposits in which the IH reaction product is
visible beneath the exposed silver grains. FIG. 6B illustrates the
adjacent section that was stained for thioflavin S and confirms the
presence and distribution of the same parenchymal amyloid deposits.
Radiolabeled parenchymal amyloid deposits were also observed in the
hippocampus and fimbria/formix of each animal. An APP, PS1
transgenic mouse injected i.v. with 200 .mu.g of
.sup.125I-A.beta..sub.1-40 did not exhibit labeling of any
parenchymal amyloid deposits, aside from faint pial and some
residual vascular labeling, with up to 12 weeks of exposure. These
results demonstrate that .sup.125I-PUT-A.beta..sub.1-40 is able to
cross the BBB and bind to amyloid deposits in vivo following i.v.
administration.
[0086] In summary, these results indicate that
.sup.125I-PUT-A.beta..sub.1-40 has increased BBB permeability
compared to .sup.125I-A.beta..sub.1-40. Also,
.sup.125I-PUT-A.beta..sub.1-40 retains its ability to selectively
label neuritic plaques in vitro, and with greater affinity than
.sup.125I-A.beta..sub.1-40. This binding does not seem to be
affected by excess unbound putrescine. APP, PS1 transgenic mice
exhibit large amounts of amyloid deposition and provide a
convenient animal model to test the ability of
.sup.125I-PUT-A.beta..sub.1-40 to label amyloid deposits in vivo.
Furthermore, .sup.125I-PUT-A.beta..sub.1-40 labels parenchymal
amyloid deposits in the brains of these mice following systemic
administration. The success of these experiments supports the
development of radiolabeled PUT-A.beta..sub.1-40 as a marker of
amyloid deposition for use as a diagnostic tool for AD in
humans.
Example 4
Molecular Targeting of Alzheimer's Amyloid Plaques for
Contrast-Enhanced MRI
[0087] The ideal MRI contrast agent for visualizing and quantifying
the pathologic burden of .beta.-amyloid plaque should have four
properties: 1) be highly stable in vivo, 2) cross the BBB
non-destructively following intravenous injection, 3) bind
specifically to parenchymal plaques with high affinity, and 4)
produce local changes in tissue contrast detectable by MRI. For
human studies, this should be feasible with clinical MRI
instrumentation. We describe experiments demonstrating that these
properties exist in putrescine-gadolinium-amyloid-.beta. peptide
(PUT-Gd-AP). In these experiments, the probe was injected into live
mice that were then sacrificed. MRI was performed on post-mortem
specimens at very high resolution (62.5 .mu.m.sup.3) in order to
prove the concept that and intravenously administered probe can
selectively produce MRI-visible plaque enhancement. Although in
vivo MRI of PUT-Gd-A.beta. plaque enhancement represents a future
experimental step that must be demonstrated before this technique
can be successfully applied to the diagnosis of AD, the present
study provides promising data to support the pursuit of further
studies.
[0088] Materials and Methods
[0089] Synthesis of A.beta. (1-40) and Modification with Gadolinium
and Putrescine. A.beta. (1-40) containing a metal chelating arm was
synthesized on a peptide synthesizer using standard protocols for
tBOC (tert-butyloxycarbonyl) chemistry. The chelating arm,
diethylenetriaminepentaacetic acid (DTPA), was attached to the
amino terminus of the peptide as the final step of synthesis. The
peptide was purified by HPLC on a C.sub.18 preparative column,
2.5.times.30 cm (Vydac Separations, Hesperia, Calif.), using linear
gradients from 0-70% of acetonitrile in 0.1% trifluoroacetic acid.
Gadolinium (Gd) was chelated to the DTPA-AP peptide using Gd (III)
chloride hexahydrate (Aldrich, Milwaukee, Wis.) with a 24-hour
incubation in water at pH 7.0 at room temperature. The
Gd-DTPA-A.beta. complex was then HPLC purified and lyophilized.
Mass spectroscopy of the HPLC-purified Gd-DTPA-A.beta. (Gd-A.beta.)
gave a mass of 4975.7, in agreement with the expected mass of
4976.6. Analytical HPLC showed a purity of >90-95%, and the
molar ratio of the A.beta. to Gd was 1:1. Polyamine modification
was performed as described previously (Poduslo and Curran, J.
Neurochem. 66:1599-1609 (1996a); Poduslo and Curran, J. Neurochem.
67:734-741 (1996b); Wengenack, et al., Brain Res. 767:128-135
(1997); Poduslo, et al., J. Neurochem. 71:1651-1660 (1998);
Poduslo, et al., Ann. Neurol. 48:943-947 (2000). One modification
to the procedure was that the PUT-Gd-A.beta. was dialyzed against
20 .mu.M gadolinium chloride instead of distilled water. This was
done as a precaution to protect against the loss of any of the
chelated Gd from the peptide, which was later determined to be
unnecessary.
[0090] PS and V.sub.p Determination in Mice. PS/V.sub.p
measurements were performed as described previously (Poduslo and
Curran, supra (1996a); Poduslo and Curran, supra (1996b);
Wengenack, et al., supra (1997); Poduslo, et al., supra (1998);
Poduslo, et al., supra (2000); Poduslo, et al., Neurobiol. Dis.
8:555-567 (2001). All procedures performed were in accordance with
NIH Guidelines for the Care and Use of Laboratory Animals. This
involved the IV bolus injection technique in which a bolus of PBS
containing .sup.125I-labeled protein was rapidly injected into the
catheterized femoral vein of anesthetized mice (sodium
pentobarbital, 25 mg/kg, IP). Blood was sampled from the femoral
artery at several intervals during the next 15 minutes. Whole blood
was sampled directly, using heparinized micro-hematocrit capillary
tubes and TCA extracted. The supernatant was separated from the
pellet and both were counted in a gamma counter. The radioactivity
in the pellet was expressed as a percentage of the total
radioactivity found in both the pellet and supernatant. An aliquot
of the peptide labeled with .sup.131I was then injected into the
femoral vein 15 seconds prior to sacrifice of the animal to serve
as a measure of residual plasma volume (V.sub.p; .mu.l/g). After
collection of the final blood sample, the anesthetized animal was
sacrificed. Several brain regions were dissected and assayed for
.sup.125I and .sup.131I radioactivity in a two-channel gamma
counter (Cobra II, Packard) with the activity corrected for
background and crossover of .sup.131I activity into the .sup.125I
channel. The permeability coefficient x surface area products (PS;
10.sup.-6 ml/g/s) were then calculated using the V.sub.p as a
measure of residual plasma volume based on equations that have been
discussed in detail elsewhere (Poduslo and Curran, supra (1996a);
Poduslo and Curran, supra (1996b); Wengenack, et al., supra (1997);
Poduslo, et al., supra (1998); Poduslo, et al., supra (2000);
Poduslo, et al., supra (2001). Statistical evaluations of PS and
V.sub.p were performed using ANOVA followed by Bonferroni multiple
comparisons.
[0091] Labeling of AD Amyloid Plaques In Vitro with Putrescine- and
Gadolinium-Labeled A.beta.. HPLC-purified .sup.125I-Gd-A.beta. 1-40
and .sup.125I-PUT-Gd-A.beta. 1-40 were incubated with sections of
unfixed AD temporal lobe cortex. Three sections were incubated with
either .sup.125I-Gd-A.beta. 1-40, .sup.125I-PUT-Gd-A.beta. 1-40, or
vehicle using the same procedure we used previously (Wengenack, et
al., Nat. Biotechnol. 18:868-872 (2000a). Briefly, the sections
were incubated for 3 hours with 100 pM .sup.125I-Gd-A.beta. 1-40 or
.sup.125I-PUT-Gd-A.beta. 1-40, or alone in 250 .mu.l of TBS
containing 0.1% BSA, 0.6 mg/ml magnesium chloride, 0.04 mg/ml
bacitracin, 0.002 mg/ml chymostatin, and 0.004 mg/ml leupeptin. The
sections then underwent immunohistochemistry (IH) for amyloid using
an anti-A.beta. monoclonal mouse antibody (4G8, 1:1000, Signet
Laboratories, Dedham, Mass.). Next, the sections were dipped in an
autoradiographic emulsion (Type NTB-3, Kodak, Rochester, N.Y.) for
direct comparison of .sup.125I-labeled amyloid deposits to
anti-A.beta. IH. The slides were dipped in emulsion, exposed, and
developed according to the instructions. The sections were
dehydrated with successive changes of ethanol and xylene and then
coverslipped.
[0092] Catheterization and Injection of Mice. The double transgenic
mice were cross-bred in-house. Hemizygous transgenic mice (mouse
strain: C57B6/SJL; I.D.# Tg2576) expressing mutant human
APP.sub.695 containing a double mutation (K670N, M671L) (Hsaio, et
al., Science 274:99-102 (1996) were mated with a strain of
homozygous transgenic mice (mouse strain: Swiss Webster/B6D2; I.D.#
M146L6.2) expressing mutant human PS1 containing a single mutation
(M146L) (Holcomb, et al., Nat. Med. 4:97-100 (1998). Each animal
was catheterized via the femoral vein under general anesthesia
(sodium pentobarbital, 25 mg/kg, IP). Two mice (one non-transgenic
and one APP-PS1) injected with PBS received a total volume of 200
.mu.l over the course of 15 minutes. A total of nine mice (two
non-transgenic, five APP-PS1, and two APP) were injected with
PUT-Gd-A.beta., receiving doses ranging from 0.4-2.0 mg. One mouse
was injected with 0.4 mg of Gd-A.beta.. Another mouse was injected
with the molar equivalent of Gd-DTPA (0.1 mg, Magnevist
(gadopentetate dimeglumine), Berlex Laboratories). After four
hours, each animal was perfused with PBS and fixed with
neutral-buffered, 10% formalin following an overdose with sodium
pentobarbital (75 mg/kg, IP). The brain was removed and fixed
further in formalin overnight and then equilibrated in 0.1 M sodium
phosphate, pH 7.4 for 24 hours. The right hemisphere was embedded
vertically in 2% agar in a 10-mm O.D. glass tube for MRI.
[0093] Magnetic Resonance Imaging. MRI was performed with a Bruker
Avance DRX-300, 89-mm vertical bore spectrometer. The glass tube
containing the embedded mouse brain was inserted into a 10-mm
diameter RF coil. T2W and T1W imaging sequences were performed with
the following parameters: field of view of 1.6 cm along the z
(vertical magnet) axis and 0.8 cm along the other two orthogonal
axes; data acquisition matrix size of 256 (along the z
axis).times.128.times.128 resulting in cubic voxels 62.5 .mu.m in
all dimensions. The signal was read out along the z-axis direction
at a bandwidth of 50 kHz. A T2W image volume with TR=3000 ms and
TE=100 ms was obtained in 13 hours, 52 minutes. A T1W image volume
with TR=400 ms and TE=8 ms and 8 signal averages was obtained in 14
hours, 42 minutes.
[0094] Thioflavin S Staining and Histological Correlation. After
MRI, the bottom of the glass MRI tube was cut off and the agar and
hemisphere extruded. The agar was then carefully cut away from the
hemisphere. A 5-mm thick block of agar was left attached to the
posterior portion of the hemisphere as a base for mounting to the
microtome platform in order to maintain the same orientation of the
hemisphere as in the MRI scan. After cryoprotecting in sucrose,
frozen coronal sections (30 .mu.m) of each hemisphere were cut with
a sliding microtome throughout the whole extent of the cerebral
cortex. The sections were mounted on slides, dried, and then
stained with fresh, filtered, aqueous 1% thioflavin S. The
thioflavin S-positive .beta.-amyloid deposits were visualized using
a confocal laser scanning microscope. Confocal images were obtained
using an argon/krypton laser and settings for fluorescein
isothiocyanate at an excitation wavelength of 488 nm and emission
of 520 nm.
[0095] In order to correlate them to the MR images, images of the
individual histologic sections were combined to create a digitized
3D volume of the specimen using an image analysis software package
(Robb, 3D Imaging in Medicine, pp. 333-361 (1990). The
through-plane voxel dimension was equal to 62.5 .mu.m in the MR
scans and 30 .mu.m in the histologic sections. In order to match
the through-plane resolution of the histologic and MR images, every
other 30-.mu.m histological section was used. The 3D T2W MRI volume
was then spatially matched to the digitized histologic volume using
common anatomic landmarks, for example the anterior commissure. The
rigid-body transformation matrix derived from the anatomic matching
procedure was saved and applied to both the T2W and T1W MR image
volumes which were resampled in the space of the digitized
histologic volume using sinc interpolation. The T2W and T1W MR
volumes were in perfect spatial registration with each other a
priori because the geometric parameters of the T2W and T1W
acquisition protocols were identical.
[0096] Results
[0097] BBB Permeability of Putrescine- and Gadolinium-Labeled
A.beta. Peptide. Our previous studies have demonstrated that
modification of proteins with endogenously occurring polyamines
such as putrescine dramatically increases their permeability at the
BBB (Poduslo and Curran, supra (1996a); Poduslo and Curran, supra
(1996b); Wengenack, et al., supra (1997); Poduslo, et al., supra
(1998): Poduslo, et al., supra (2000). In addition, we have
demonstrated that putrescine-modified A.beta. has a highly
significant 1.9-2.3 fold increase in the permeability
coefficient-surface area product (PS) in six different brain
regions as compared to the native, unmodified A.beta. (Wengenack,
et al., supra (2000a). It was possible, however, that Gd labeling
for MRI contrast purposes would significantly reduce the BBB
permeability of PUT-A.beta.. In order to test this hypothesis, the
BBB permeabilities of the Gd-labeled and PUT- and Gd-labeled
A.beta. peptides were measured in non-transgenic mice.
[0098] The BBB permeabilities of Gd-labeled A.beta. (Gd-A.beta.)
and PUT- and Gd-labeled A.beta. (PUT-Gd-AP) were quantified in
different brain regions of non-transgenic mice using an IV bolus
injection technique with correction for the residual blood volume
(V.sub.p) (Table 2).
TABLE-US-00002 TABLE 2 PS and V.sub.p of A.beta., PUT-A.beta.,
Gd-A.beta., and PUT-Gd-A.beta. at the BBB in Non-Transgenic Mice
A.beta. PUT-A.beta. Gd-A.beta. PUT-Gd-A.beta. Brain Region (n = 14)
(n = 8) RI P (n = 8) RI P (n = 7) RI P PS Cortex 52.3 .+-. 3.4
125.7 .+-. 7.6 2.4 *** 32.4 .+-. 3.8 0.6 ns 91.3 .+-. 9.5 1.7 ***
Caudate-Putamen 41.0 .+-. 3.2 99.6 .+-. 4.6 2.4 *** 23.5 .+-. 3.1
0.6 ns 60.0 .+-. 9.0 1.5 * Hippocampus 48.7 .+-. 3.2 105.5 .+-. 6.9
2.2 *** 30.5 .+-. 3.2 0.6 * 84.2 .+-. 6.8 1.7 *** Thalamus 50.8
.+-. 3.4 123.3 .+-. 6.5 2.4 *** 32.4 .+-. 3.7 0.6 ns 83.1 .+-. 12.5
1.6 ** Brain Stem 61.6 .+-. 4.1 155.1 .+-. 19.0 2.5 *** 45.3 .+-.
5.2 0.7 ns 125.8 .+-. 8.9 2.0 *** Cerebellum 65.5 .+-. 4.5 159.2
.+-. 9.4 2.4 *** 42.9 .+-. 4.9 0.7 ns 113.3 .+-. 12.5 1.7 ***
V.sub.p Cortex 14.3 .+-. 1.0 40.4 .+-. 2.5 2.8 *** 16.8 .+-. 0.6
1.2 ns 58.2 .+-. 2.7 4.1 *** Caudate-Putamen 9.8 .+-. 0.9 31.5 .+-.
1.9 3.2 *** 9.1 .+-. 0.5 0.9 ns 43.4 .+-. 2.2 4.4 *** Hippocampus
15.6 .+-. 1.3 35.9 .+-. 2.9 2.3 *** 15.4 .+-. 0.7 1.0 ns 52.2 .+-.
3.3 3.3 *** Thalamus 13.0 .+-. 0.9 40.5 .+-. 2.7 3.1 *** 15.8 .+-.
0.6 1.2 ns 58.8 .+-. 2.6 4.5 *** Brain Stem 17.3 .+-. 1.3 46.3 .+-.
3.0 2.7 *** 19.3 .+-. 1.2 1.1 ns 63.5 .+-. 3.6 3.7 *** Cerebellum
20.8 .+-. 1.6 54.5 .+-. 2.1 2.6 *** 22.4 .+-. 1.0 1.1 ns 73.4 .+-.
3.7 3.5 *** PS: Permeability coefficient-surface area product
(ml/g/s .times. 10.sup.-6, x .+-. SEM) determined with
.sup.125I-A.beta. derivatives over the course of 15 min and
corrected for V.sub.p. V.sub.p: Residual brain region blood volume
(.mu.l/g, x .+-. SEM) determined with .sup.131I-A.beta. derivatives
given 15 sec prior to end of experiment. RI: relative increase
versus A.beta.. P: ANOVA with Bonferroni mulitple comparisons
versus A.beta.: ns--not significant (P > 0.05); * P < 0.05;
** P < 0.01; *** P < 0.001.
[0099] Polyamine modification resulted in a significant 2.2-2.5
fold increase in the PS values. Not surprisingly, when A.beta. was
labeled with gadolinium, there was a decrease in the PS value in
five of the six brain regions, however, this was of non-significant
magnitude. Interestingly, after putrescine modification of the
Gd-A.beta., this decrease in permeability was partially rescued.
These PS values were all highly significantly increased by 1.5-2.0
fold compared to A.beta. and represented only a 19-40% decrease in
the PS values compared to PUT-A.beta. in the different brain
regions.
[0100] The V.sub.p values for A.beta., PUT-A.beta., Gd-A.beta., and
PUT-Gd-A.beta. were also measured in six different brain regions in
non-transgenic mice (Table 2). After putrescine modification of
A.beta., the V.sub.p values increased significantly by 2.3-3.2
fold. These increases are probably the result of the large
increases in the PS values observed for PUT-A.beta. with some of
the peptide crossing the BBB even during the short, 15-second time
interval for the administration of the second isotope. This
observation has been made for several proteins that have high BBB
permeabilities and suggests that the PS values are an
underestimation. The V.sub.p values for Gd-A.beta. were not
significantly different from those of A.beta.. The PUT-Gd-A.beta.,
however, showed a significant increase that ranged from 3.3-4.5
fold compared to A.beta.. In summary, gadolinium modification had a
relatively small effect on the BBB permeability of A.beta., which
was rescued by polyamine modification. This high permeability
should allow it to access the brain's parenchyma after systemic
administration in the same manner as has been described for
radioiodinated PUT-A.beta. (Wengenack, et al., supra (2000a).
Although the permeability measurements performed in the present
study do not directly measure the amount of PUT-Gd-A.beta. in the
brain, in a previous study (Wengenack, et al., supra (2001a) we
measured the amount of radiolabeled PUT-A.beta. in PBS-perfused
brain following IV injection. There was greater than 10-fold more
.sup.125I-PUT-A.beta. present in the brain compared to
.sup.125I-A.beta. (0.35% vs. 0.03%, respectively) four hours after
injection of equal doses. This not only confirms the higher
permeability values of PUT-A.beta. compared to A.beta., but also
indicates that a substantial fraction of the injected dose enters
the brain. Since PUT-Gd-A.beta. exhibits similar increases in
permeability values it is likely that it also enters the brain in
sufficient quantity.
[0101] Labeling of AD Amyloid Plaques In Vitro with Putrescine- and
Gadolinium-Labeled A.beta. Peptides. The next step was to determine
if Gd modification had any effect on the ability of A.beta. or
PUT-A.beta. to label .beta.-amyloid plaques in human AD brain
sections in vitro, as reported previously by us (Wengenack, et al.,
supra (2000a). Our results showed the detection of radiolabeled
Gd-A.beta. or PUT-Gd-A.beta. binding to plaques in vitro in AD
brain tissue processed with anti-A.beta. immunohistochemistry and
emulsion autoradiography. As indicated, .sup.125I-PUT-Gd-A.beta. is
able to bind to plaques, and at a higher level than
.sup.125I-Gd-A.beta.. This is apparent because
.sup.125I-PUT-Gd-A.beta. required an exposure time of only one day,
whereas the .sup.125I-Gd-A.beta. required an exposure time of nine
days following application of equal amounts of radioactivity. The
putrescine modification, therefore, allows for a dramatic increase
in the binding of A.beta. to plaques even in the presence of the
gadolinium modification. These studies demonstrate that
PUT-Gd-A.beta. retains the same plaque binding properties as
described previously for PUT-A.beta. (Wengenack, et al., supra
(2000a), and therefore could likely function as an MRI probe to
target plaques after IV administration.
[0102] MRI-Histologic Correlation in APP-PS1 Mice Injected with
PUT-Gd-A.beta.. The main objective of this study was to test the
hypothesis that enhanced MRI contrast features consistent with
selective binding of PUT-Gd-A.beta. to .beta.-amyloid plaques are
present after IV administration in AD transgenic mice. Transgenic
mice that express two mutant human proteins associated with
familial AD, amyloid precursor protein (APP) and presenilin 1
(PS1), were used in these experiments (Holcomb, et al., supra
(1998). These mice develop .beta.-amyloid deposits and behavioral
deficits within 12 weeks of age. Amyloid burden increases an
average of 179-fold from 12 to 52 weeks of age (0.02% to 3.57%) in
the cortex and hippocampus (Wengenack, et al., supra (2000b).
Therefore, these mice provide an appropriate animal model to test
this hypothesis.
[0103] APP-PS1 transgenic mice (1 year of age) were injected IV
with PUT-Gd-A.beta.. After four hours, each mouse was sacrificed,
perfused, and its brain removed for imaging. T2- and T1-weighted
(T2W and T1W, respectively) MR imaging sequences were performed at
7 Tesla. After MRI, the hemispheres were sectioned, stained with
thioflavin S, and then correlated with the MR images. Once the
histologic and MR volumes had been registered into the same spatial
coordinate system, a linked cursor was used to identify common
coordinate positions in the histologic specimen and the two MR
image volumes. The ability to position the cursor at any location
in one image and visualize that precise anatomic location in the
other registered image volumes was used to identify and compare the
appearance of plaques that were captured equivalently on the
thioflavin S and MR images. A photomicrograph of thioflavin
S-stained histologic section and the corresponding T2W and T1W MR
images shows numerous focal areas. Numerous focal areas of
accelerated T2 relaxation are visible as dark spots on the T2W
image in regions with abundant thioflavin S-positive plaques, such
as the cortex and hippocampus. Although it was impossible to obtain
a direct one-to-one correlation between every thioflavin S-positive
plaque in the histological section and every area of accelerated T2
relaxation, many plaques could be unequivocally matched and five
representative plaques are labeled. There were also many focal
areas of accelerated T1 relaxation visible as bright spots on the
T1W images that directly corresponded to plaques in the thioflavin
S section. These results were typical for all the APP-PS1 mice
injected with PUT-Gd-A.beta.. This pattern suggested that
PUT-Gd-A.beta. crossed the BBB, labeled amyloid plaques, and could
be detected by MRI.
[0104] MRI-Histologic Correlation in a Non-Transgenic Mouse. We
next wished to test the hypothesis that the features visible on the
T2W and T1W MR images described in the previous section were
specific for amyloid plaques in the transgenic mouse. The same
procedures for animal preparation, MRI, and MRI-histologic
correlation described in the previous section were carried out on a
non-transgenic mouse injected with phosphate-buffered saline (PBS).
As expected, the thioflavin S sections showed no staining, and no
evidence of focal areas of accelerated T1 relaxation were observed
on the corresponding MR sections. Although focal areas of
accelerated T2 relaxation were not apparent in the cortex, some
were present in the striatum, illustrating that this is not an
imaging feature specific for amyloid plaques. A non-transgenic
mouse injected with PUT-Gd-A.beta. yielded the same results. We
concluded that the focal areas of accelerated T1 relaxation
observed in transgenic mice injected with PUT-Gd-A.beta. were
enhanced plaques and not a non-specific feature of IV-injected
PUT-Gd-A.beta..
[0105] MRI-Histologic Correlation in an APP-PS1 Mouse Injected with
PBS. We next performed a control experiment in an APP-PS1
transgenic mouse injected with PBS. This experiment was done for
two reasons. First, we wished to test the hypothesis that plaques
in this AD transgenic mouse model had the same MR contrast
properties without the addition of a contrast agent as had been
demonstrated in human ex vivo tissue (Benveniste, et al., Proc.
Natl. Acad. Sci. USA 96:14079-14084 (1999). Second, we had to
establish the baseline appearance of plaques on T2W and T1W MR
images in the absence of the PUT-Gd-A.beta. contrast agent. Animal
preparation, MRI, and histologic correlation were performed as
described above. Focal areas of accelerated T2 relaxation were
present in the T2W image that corresponded to plaques in the
thioflavin S section, but none were apparent in the T1W image.
Plaques therefore accelerated the T2 relaxation rate, but had no
appreciable effect on the T1 relaxation of brain tissue in the
absence of PUT-Gd-A.beta.. This further supports the observation in
the PUT-Gd-A.beta.-injected APP-PS1 mice that focal areas of
accelerated T1 relaxation represent plaques labeled with
PUT-Gd-A.beta..
[0106] MRI-Histologic Correlation in an APP-PS1 Mouse Injected with
Gd-DTPA. We also wished to rule out the possibility that the MR
contrast properties observed with IV injection of PUT-Gd-A.beta.
were a non-specific effect of intravascular Gd in the APP-PS1
mouse. In order to test this hypothesis, an APP-PS1 transgenic
mouse was injected IV with a molar equivalent amount of Gd-DTPA.
The resulting T2W images showed the expected focal areas of T2
acceleration that corresponded to plaques. No evidence of T1 plaque
enhancement was seen in the T1W images, however. This experiment
confirmed our hypothesis that plaque enhancement is a specific
feature of PUT-Gd-A.beta. and not a non-specific effect of
intravascular Gd.
[0107] MRI-Histologic Correlation in an APP-PS1 Mouse Injected with
Gd-A.beta.. The first two experiments of this study demonstrated
that both BBB transport and binding of Gd-A.beta. to plaques is
greatly enhanced by PUT modification. However, since Gd-A.beta.
without the addition of putrescine was also shown to label plaques
in vitro, albeit at a much lower level, in a final experiment we
tested the hypothesis that PUT modification of the Gd-A.beta.
molecule is necessary to obtain observable T1 relaxation of plaques
following IV injection. In an APP-PS1 transgenic mouse injected IV
with Gd-A.beta., accelerated T2 relaxation was observed in plaques
as expected, but no significant plaque enhancement was observed on
T1W images. Based on this series of primary and control
experiments, we conclude that the accelerated T1 relaxation
observed could only be the result of the presence of PUT-Gd-A.beta.
in the plaques.
[0108] Quantitative Voxel Intensity Measurements. Although the
images themselves seem convincing enough to prove the hypothesis
that PUT-Gd-A.beta. specifically labels plaques in vivo and is
detectable by MRI, quantitative measurements were also performed.
Intensity measurements were performed on plaques represented
equivalently in the histologic and T2W images in order to
quantitate the T2 and T1 contrast properties of individual plaques
under varying experimental conditions. The plaque-to-background
voxel intensity ratios (PBR) for individual plaques were calculated
as the minimum (T2) or maximum (T1) intensity value within a region
of interest (ROI) drawn around each plaque, divided by the
intensity of adjacent, normal appearing background tissue. The
background intensity was calculated as the average of the mean
intensities of three 4-voxel.sup.2 regions sampled adjacent to each
plaque. To eliminate any bias in quantifying plaque contrast
enhancement, plaques measured were visible in both the thioflavin S
image and the T2W image without prior viewing of the T1W image. The
ROI was then positioned in the T1W image at the same coordinates as
in the T2W image and the maximum intensity recorded. The PBRs were
significantly decreased for the T2W images and significantly
increased for the T1 W images in APP-PS1 mice injected with
PUT-Gd-A.beta. compared to APP-PS1 mice injected with PBS (Table
3).
TABLE-US-00003 TABLE 3 Plaque-to-Background Voxel Intensity Ratios
and Contrast-to-Noise Ratios of Amyloid Plaques Compared to
Background in T2 and T1 MRI Scans of AD Transgenic Mouse Brain T2
T1 Probe PBR.sup.a CNR.sup.b PBR.sup.a CNR.sup.b PBS 0.59 .+-. 0.03
-4.95 .+-. 0.31 1.02 .+-. 0.01 0.76 .+-. 0.26 Gd-A.beta. 0.48 .+-.
0.03 -6.18 .+-. 0.43 1.03 .+-. 0.01 1.71 .+-. 0.28 PUT-Gd-A.beta.
0.29 .+-. 0.03*** -8.95 .+-. 0.53*** 1.24 .+-. 0.04*** 7.13 .+-.
1.03*** .sup.aThe plaque-to-background voxel intensity ratios (PBR,
mean .+-. SEM, n = 15) were calculated as the minimum (T2) or
maximum (T1) intensity value within a region drawn around each
plaque divided by the background intensity, which was the average
of the mean intensities of three 4-voxel.sup.2 regions sampled
adjacent to each plaque. Cubic voxel size = 62.5 .mu.m on a side.
***P < 0.001 vs. PBS by Bonferroni post-hoc comparison performed
following one-way ANOVAs: T2 - [F(2, 44) = 28.98; P < 0.0001],
T1 - [F(2, 44) = 29.31; P < 0.0001]. .sup.bThe contrast-to-noise
ratios (CNR, mean .+-. SEM, n = 15) were calculated as the minimum
(T2) or maximum (T1) intensity value of each plaque minus the
background intensity divided by the standard deviation of the
noise. The noise was measured in a 144-.mu.m.sup.2 area of agar
adjacent to the tissue. ***P < 0.001 vs. PBS by Bonferroni
post-hoc comparison performed following one-way ANOVAs: T2 - [F(2,
44) = 29.32; P < 0.0001], T1 - [F(2, 44) = 22.38; P <
0.0001].
[0109] IV injection of Gd-A.beta. slightly decreased the T2 PBRs
(not significantly, however), but had no effect on the T1 PBRs
(Table 3).
[0110] Plaque-to-background tissue contrast-to-noise ratios (CNR)
were also calculated. CNRs were calculated as the minimum (T2) or
maximum (T1) intensity value of each plaque minus the background
tissue intensity divided by root mean square (RMS) noise. RMS noise
was measured as the standard deviation in a region of interest
placed over the agar adjacent to the tissue in each image. Like the
PBRs, the CNRs were significantly decreased for the T2 images and
significantly increased for the T1 images in APP-PS1 mice injected
with PUT-Gd-A.beta. compared to APP-PS1 mice injected with PBS
(Table 3). The CNRs for the T1 images, however, showed a more
dramatic increase in the PUT-Gd-A.beta.-injected mice compared to
the PBRs (4.2-9.4 fold vs. 1.2-fold). These quantitative results
are best explained by: 1) transport of the intact PUT-Gd-A.beta.
molecule across the BBB, 2) binding of the complex specifically to
plaques, and 3) enhancement of both T2 and T1 relaxation of tissue
water by the complex in plaques.
[0111] In order to further support the likelihood of successfully
visualizing labeled plaques in vivo, we developed an imaging metric
that crudely approximates histologic measures of labeled tissue
volume fraction. Measurements were performed on the T1W images of
the APP-PS1 mouse injected with PUT-Gd-A.beta.. We measured the
number of pixels in cortical ROIs whose signal intensity exceeded 4
S.D. above the mean intensity of normal background cortical tissue.
An 812.5.times.812.5 .mu.m ROI was selected. Within this larger
ROI, a smaller region (125.0.times.187.5 .mu.m) of normal appearing
(background) cortical tissue was selected and its mean signal
intensity and S.D. measured. Pixels whose intensity was .gtoreq.4
S.D. above this mean were then regarded to lie outside (above) the
normal distribution of pixel intensities of non-enhanced tissue.
Within the 812.5.times.812.5 .mu.m cortical ROI, we then measured
the proportion of pixels whose signal intensity exceeded the normal
range by 4 S.D. in 10 consecutive T1W images with the ROI in the
same position in the hemisphere. This proportion was interpreted to
represent the volume fraction of labeled (i.e., enhanced) plaques.
Pixels that met this criteria clearly corresponded to enhanced
plaques. The mean (.+-.S.D.) proportion of pixels within the ROI
whose intensity exceeded the 4-S.D. threshold across 10 images was
9.9% (.+-.8.9%). We interpret this to indicate that roughly 10% of
the cortical tissue volume in this mouse was occupied by plaque
that enhanced to a sufficient degree that it was easily
distinguished from normal background tissue.
* * * * *